Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Immune Effector Functions of Human IgG2 Antibodies against EGFR.

Rösner T, Kahle S, Montenegro F, Matlung HL, Jansen JHM, Evers M, Beurskens F, Leusen JHW, van den Berg TK, Valerius T.

Mol Cancer Ther. 2019 Jan;18(1):75-88. doi: 10.1158/1535-7163.MCT-18-0341. Epub 2018 Oct 3.

PMID:
30282813
2.

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis.

Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, Franke K, Schornagel K, Verkuijlen P, Janssen H, Halonen P, Lieftink C, Beijersbergen RL, Leusen JHW, Boelens JJ, Kuhnle I, van der Werff Ten Bosch J, Seeger K, Rutella S, Pagliara D, Matozaki T, Suzuki E, Menke-van der Houven van Oordt CW, van Bruggen R, Roos D, van Lier RAW, Kuijpers TW, Kubes P, van den Berg TK.

Cell Rep. 2018 Jun 26;23(13):3946-3959.e6. doi: 10.1016/j.celrep.2018.05.082.

3.

Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells.

Treffers LW, Zhao XW, van der Heijden J, Nagelkerke SQ, van Rees DJ, Gonzalez P, Geissler J, Verkuijlen P, van Houdt M, de Boer M, Kuijpers TW, van den Berg TK, Matlung HL.

Eur J Immunol. 2018 Feb;48(2):344-354. doi: 10.1002/eji.201747215. Epub 2017 Nov 2.

PMID:
28952147
4.

The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.

Matlung HL, Szilagyi K, Barclay NA, van den Berg TK.

Immunol Rev. 2017 Mar;276(1):145-164. doi: 10.1111/imr.12527. Review.

PMID:
28258703
5.

Immune checkpoint blockade: Which switches to hit and how much?

Matlung HL, Szilagyi K, Kuijpers TW, van Lier RAW, van den Berg TK.

Immunol Lett. 2016 Dec;180:73-74. doi: 10.1016/j.imlet.2016.08.014. Epub 2016 Sep 20. No abstract available.

PMID:
27662791
6.

Neutrophils in cancer.

Treffers LW, Hiemstra IH, Kuijpers TW, van den Berg TK, Matlung HL.

Immunol Rev. 2016 Sep;273(1):312-28. doi: 10.1111/imr.12444. Review.

PMID:
27558343
7.

Immunoreceptors on neutrophils.

van Rees DJ, Szilagyi K, Kuijpers TW, Matlung HL, van den Berg TK.

Semin Immunol. 2016 Apr;28(2):94-108. doi: 10.1016/j.smim.2016.02.004. Epub 2016 Mar 11. Review.

PMID:
26976825
8.

Regulation of Phagocyte Migration by Signal Regulatory Protein-Alpha Signaling.

Alvarez-Zarate J, Matlung HL, Matozaki T, Kuijpers TW, Maridonneau-Parini I, van den Berg TK.

PLoS One. 2015 Jun 9;10(6):e0127178. doi: 10.1371/journal.pone.0127178. eCollection 2015.

9.

IFN-γ priming of macrophages represses a part of the inflammatory program and attenuates neutrophil recruitment.

Hoeksema MA, Scicluna BP, Boshuizen MC, van der Velden S, Neele AE, Van den Bossche J, Matlung HL, van den Berg TK, Goossens P, de Winther MP.

J Immunol. 2015 Apr 15;194(8):3909-16. doi: 10.4049/jimmunol.1402077. Epub 2015 Mar 6.

10.

The guanine-nucleotide exchange factor SGEF plays a crucial role in the formation of atherosclerosis.

Samson T, van Buul JD, Kroon J, Welch C, Bakker EN, Matlung HL, van den Berg TK, Sharek L, Doerschuk C, Hahn K, Burridge K.

PLoS One. 2013;8(1):e55202. doi: 10.1371/journal.pone.0055202. Epub 2013 Jan 25.

11.

On the mechanism of CD47 targeting in cancer.

Zhao XW, Matlung HL, Kuijpers TW, van den Berg TK.

Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2843; author reply E2844-5. doi: 10.1073/pnas.1209265109. Epub 2012 Aug 24. No abstract available.

12.

Transglutaminase activity regulates atherosclerotic plaque composition at locations exposed to oscillatory shear stress.

Matlung HL, Neele AE, Groen HC, van Gaalen K, Tuna BG, van Weert A, de Vos J, Wentzel JJ, Hoogenboezem M, van Buul JD, VanBavel E, Bakker EN.

Atherosclerosis. 2012 Oct;224(2):355-62. doi: 10.1016/j.atherosclerosis.2012.07.044. Epub 2012 Aug 7.

13.

The redox state of transglutaminase 2 controls arterial remodeling.

van den Akker J, VanBavel E, van Geel R, Matlung HL, Guvenc Tuna B, Janssen GM, van Veelen PA, Boelens WC, De Mey JG, Bakker EN.

PLoS One. 2011;6(8):e23067. doi: 10.1371/journal.pone.0023067. Epub 2011 Aug 25.

14.

Role of transglutaminases in cuff-induced atherosclerotic lesion formation in femoral arteries of ApoE3 Leiden mice.

Matlung HL, VanBavel E, van den Akker J, de Vries CJ, Bakker EN.

Atherosclerosis. 2010 Nov;213(1):77-84. doi: 10.1016/j.atherosclerosis.2010.07.054. Epub 2010 Aug 11.

PMID:
20810110
15.

Nuclear receptor Nur77 inhibits vascular outward remodelling and reduces macrophage accumulation and matrix metalloproteinase levels.

Bonta PI, Matlung HL, Vos M, Peters SL, Pannekoek H, Bakker EN, de Vries CJ.

Cardiovasc Res. 2010 Aug 1;87(3):561-8. doi: 10.1093/cvr/cvq064. Epub 2010 Feb 26.

PMID:
20189954
16.

Strain-dependent susceptibility for hypertension in mice resides in the natural killer gene complex.

Taherzadeh Z, VanBavel E, de Vos J, Matlung HL, van Montfrans G, Brewster LM, Seghers L, Quax PH, Bakker EN.

Am J Physiol Heart Circ Physiol. 2010 Apr;298(4):H1273-82. doi: 10.1152/ajpheart.00508.2009. Epub 2010 Feb 12.

17.

Calcification locates to transglutaminases in advanced human atherosclerotic lesions.

Matlung HL, Groen HC, de Vos J, van Walsum T, van der Lugt A, Niessen WJ, Wentzel JJ, Vanbavel E, Bakker EN.

Am J Pathol. 2009 Oct;175(4):1374-9. doi: 10.2353/ajpath.2009.090012. Epub 2009 Aug 28.

18.

Shear stress, reactive oxygen species, and arterial structure and function.

Matlung HL, Bakker EN, VanBavel E.

Antioxid Redox Signal. 2009 Jul;11(7):1699-709. doi: 10.1089/ARS.2008.2408. Review.

PMID:
19186981
19.

Blood flow-dependent arterial remodelling is facilitated by inflammation but directed by vascular tone.

Bakker EN, Matlung HL, Bonta P, de Vries CJ, van Rooijen N, Vanbavel E.

Cardiovasc Res. 2008 May 1;78(2):341-8. doi: 10.1093/cvr/cvn050. Epub 2008 Feb 24.

PMID:
18299286

Supplemental Content

Loading ...
Support Center